Extended-Release ADHD Drug

20:00 EDT 31 Jul 2017 | JAMA

Another extended-release amphetamine-dextroamphetamine combination medication has received approval for the treatment of attention-deficit/hyperactivity disorder (ADHD). Marketed as Mydayis, the drug is indicated for teens and adults. Children aged 12 years or younger should not take the drug.

Original Article: Extended-Release ADHD Drug


More From BioPortfolio on "Extended-Release ADHD Drug"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...